Evidence-based clinical practice guidelines for inflammatory bowel disease

Journal of Gastroenterology

Volumn 53, Issue 3, 2018, Pages 305-353

  Matsuoka, Katsuyoshi ^a   Kobayashi, Taku ^a   Ueno, Fumiaki ^a,b   Matsui, Toshiyuki ^a   Hirai, Fumihito ^a   Inoue, Nagamu ^a   Kato, Jun ^a   Kobayashi, Kenji ^a   Kobayashi, Kiyonori ^a   Koganei, Kazutaka ^a   Kunisaki, Reiko ^a   Motoya, Satoshi ^a   Nagahori, Masakazu ^a   Nakase, Hiroshi ^a   Omata, Fumio ^a   Saruta, Masayuki ^a   Watanabe, Toshiaki ^a   Tanaka, Toshiaki ^a   Kanai, Takanori ^a   Noguchi, Yoshinori ^a   Takahashi, Ken ichi ^a   Watanabe, Kenji ^a   Hibi, Toshifumi ^a   Suzuki, Yasuo ^a   Watanabe, Mamoru ^a   Sugano, Kentaro ^a   Shimosegawa, Tooru ^a   more..

^a Guidelines Committee for Creating and Evaluating the Evidence Based Clinical Practice Guidelines for Inflammatory Bowel Disease in Japan   (Japan)

^b OFUNA CHUO HOSPITAL   (Japan)

Author keywords

Consensus; Crohn s disease; Evidence; Guidelines; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CANCER EPIDEMIOLOGY; CLINICAL FEATURE; CROHN DISEASE; DELPHI STUDY; EVIDENCE BASED PRACTICE; HUMAN; INFLAMMATORY BOWEL DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; ULCERATIVE COLITIS; CONSENSUS; EARLY CANCER DIAGNOSIS; JAPAN; PATHOPHYSIOLOGY; PROCTOCOLECTOMY; RISK FACTOR;

COLITIS, ULCERATIVE; CONSENSUS; CROHN DISEASE; EARLY DETECTION OF CANCER; HUMANS; JAPAN; PROCTOCOLECTOMY, RESTORATIVE; RISK FACTORS;

EID: 85041923106     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-018-1439-1     Document Type: Review

References (316)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23 (quiz 24. Epub 2010/01/14).
2. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104(2):465–83 (quiz 4, 84. Epub 2009/01/29).
3. Japan Intractable Diseases Information Center. http://www.nanbyou.or.jp.
4. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–24 (Epub 2012/11/07).
5. Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005;11(2):154–63 (Epub 2005/01/29).
6. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462–71 (Epub 2006/11/24).
7. Koutroubakis IE, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. Am J Gastroenterol. 2000;95(1):171–6 (Epub 2000/01/19).
8. Cornish JA, Tan E, Simillis C, et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103(9):2394–400 (Epub 2008/08/08).
9. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case–control study. Am J Gastroenterol. 2000;95(8):1949–54 (Epub 2000/08/19).
10. Kaplan GG, Jackson T, Sands BE, et al. The risk of developing Crohn’s disease after an appendectomy: a meta-analysis. Am J Gastroenterol. 2008;103(11):2925–31 (Epub 2008/09/09).
11. Munakata A. Draft revision of diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 1998. p. 96–9.
12. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955;2(4947):1041–8 (Epub 1955/10/29).
13. Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996;334(13):841–8 (Epub 1996/03/28).
14. Matsui T. Draft revision of diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2010. p. 484–8.
15. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6(1):8–15 (Epub 2000/03/04).
16. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–44 (Epub 1976/03/11).
17. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet (Lond, Engl). 1980;1(8167):514 (Epub 1980/03/08).
18. Matsui T. Draft diagnostic criteria for Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2013. p. 43–5.
19. Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108(1):83–9 (Epub 2012/09/26).
20. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506–13 (Epub 2000/09/15).
21. Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterology. 2004;126(6):1561–73 (Epub 2004/05/29).
22. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571–607 (Epub 2011/04/06).
23. Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2(1):1–23 (Epub 2008/03/01).
24. Fukuchi T, Nakase H, Matsuura M, et al. Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. J Crohns Colitis. 2013;7(10):803–11 (Epub 2013/01/29).
25. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9 (Epub 1987/12/24).
26. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ (Clin Res Ed). 1989;298(6666):82–6 (Epub 1989/01/14).
27. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983–9 (Epub 1989/07/01).
28. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13(9):1100–5 (Epub 2007/05/18).
29. Pera A, Bellando P, Caldera D, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987;92(1):181–5 (Epub 1987/01/01).
30. Witte AM, Veenendaal RA, Van Hogezand RA, et al. Crohn’s disease of the upper gastrointestinal tract: the value of endoscopic examination. Scand J Gastroenterol Suppl. 1998;225:100–5 (Epub 1998/03/27).
31. Schmitz-Moormann P, Schag M. Histology of the lower intestinal tract in Crohn’s disease of children and adolescents. Multicentric Paediatric Crohn’s Disease Study. Pathol Res Pract. 1990;186(4):479–84 (Epub 1990/08/01).
32. De Matos V, Russo PA, Cohen AB, Finkel Y. Frequency and clinical correlations of granulomas in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46(4):392–8 (Epub 2008/03/28).
33. Rubio CA, Orrego A, Nesi G, et al. Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn’s colitis. J Clin Pathol. 2007;60(11):1268–72 (Epub 2007/02/13).
34. Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2010;105(6):1240–8 (quiz 9. Epub 2009/12/24).
35. Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy. 2009;41(7):618–37 (Epub 2009/07/10).
36. Matsui T. Draft diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2011. p. 479–83.
37. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982–1018 (Epub 2013/11/05).
38. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7(7):556–85 (Epub 2013/04/16).
39. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965–90 (Epub 2012/10/09).
40. Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology. 2008;247(1):64–79 (Epub 2008/03/29).
41. Hollerbach S, Geissler A, Schiegl H, et al. The accuracy of abdominal ultrasound in the assessment of bowel disorders. Scand J Gastroenterol. 1998;33(11):1201–8 (Epub 1998/12/29).
42. Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000;43(10 Suppl):S85–93 (Epub 2000/10/29).
43. Hisabe T, Hirai F, Matsui T, et al. Evaluation of diagnostic criteria for Crohn’s disease in Japan. J Gastroenterol. 2014;49(1):93–9 (Epub 2013/04/03).
44. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4(1):7–27 (Epub 2010/12/03).
45. Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34(2):125–45 (Epub 2011/05/28).
46. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn’s disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68(2):255–66 (Epub 2008/06/03).
47. Giles E, Barclay AR, Chippington S, et al. Systematic review: MRI enterography for assessment of small bowel involvement in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2013;37(12):1121–31 (Epub 2013/05/04).
48. Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology. 2009;251(3):751–61 (Epub 2009/03/12).
49. Beaugerie L, Massot N, Carbonnel F, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001;96(7):2113–6 (Epub 2001/07/27).
50. Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008;23(12):1213–21 (Epub 2008/09/03).
51. Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8(8):717–25 (Epub 2014/03/19).
52. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology. 2002;123(3):707–13 (Epub 2002/08/29).
53. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther. 2003;17(12):1451–7 (Epub 2003/06/26).
54. Seksik P, Nion-Larmurier I, Sokol H, et al. Effects of light smoking consumption on the clinical course of Crohn’s disease. Inflamm Bowel Dis. 2009;15(5):734–41 (Epub 2008/12/11).
55. Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120(5):1093–9 (Epub 2001/03/27).
56. Swanson GR, Sedghi S, Farhadi A, et al. Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol (Fayettev, NY). 2010;44(3):223–8 (Epub 2010/08/05).
57. Ford AC, Khan KJ, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):167–76 (author reply 77. Epub 2011/11/24).
58. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):Cd004115 (Epub 2010/01/22).
59. Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;11:Cd004118 (Epub 2012/11/16).
60. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:Cd000543 (Epub 2012/10/19).
61. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:Cd000544 (Epub 2012/10/19).
62. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;(12):Cd008870 (Epub 2010/12/15).
63. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2004;2(5):379–88 (Epub 2004/05/01).
64. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):Cd003715 (Epub 2005/01/28).
65. Gordon M, Naidoo K, Thomas AG, Moss AC. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2011;(1):Cd008414 (Epub 2011/01/21).
66. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345–53 (Epub 2005/06/03).
67. O’Connor A, Packey CD, Akbari M, et al. Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: an agent-specific systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(11):2562–9 (Epub 2015/08/22).
68. Nguyen GC, Gulamhusein A, Bernstein CN. 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012;107(9):1298–304 (quiz 7, 305. Epub 2012/07/04).
69. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–9 (quiz 600. Epub 2011/03/17).
70. Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;(2):Cd006792 (Epub 2008/04/22).
71. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003;(4):Cd000301 (Epub 2003/10/30).
72. Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet (Lond, Engl). 1965;1(7378):188–9 (Epub 1965/01/23).
73. Powell-Tuck J, Bown RL, Chambers TJ, et al. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion. 1981;22(5):263–70 (Epub 1981/01/01).
74. Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32(4):337–50 (Epub 2014/05/14).
75. Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;(6):Cd000296 (Epub 2015/06/04).
76. Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):Cd002913 (Epub 2009/01/23).
77. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):630–42 (Epub 2011/03/17).
78. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;(9):Cd000478 (Epub 2012/09/14).
79. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):Cd000067 (Epub 2009/01/23).
80. Chatu S, Subramanian V, Saxena S, et al. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(1):23–34 (quiz 5. Epub 2013/12/11).
81. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104(8):2089–96 (Epub 2009/07/02).
82. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2013;(4):Cd000545 (Epub 2013/05/02).
83. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5 (Epub 2005/07/13).
84. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (Lond, Engl). 2009;374(9701):1617–25 (Epub 2009/10/20).
85. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–15.e3 (Epub 2013/07/31).
86. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2014;8(1):31–44 (Epub 2013/06/01).
87. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103(7):1783–800 (Epub 2008/06/19).
88. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;(3):Cd007216 (Epub 2008/07/23).
89. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18(5):803–8 (Epub 2011/09/03).
90. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;(1):Cd004277 (Epub 2005/01/28).
91. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (Lond, Engl). 2012;380(9857):1909–15 (Epub 2012/10/16).
92. Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(10):599–608 (Epub 2012/08/22).
93. Morikawa K, Watabe H, Araake M, et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother. 1996;40(6):1366–70 (Epub 1996/06/01).
94. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661–73 (Epub 2011/03/17).
95. Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012;4(6):1051–6 (Epub 2012/12/12).
96. Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci. 2007;52(11):2920–5 (Epub 2007/04/07).
97. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet (Lond, Engl). 1974;1(7866):1067–70 (Epub 1974/06/01).
98. Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105(8):1820–9 (Epub 2010/03/11).
99. Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;(6):Cd001176 (Epub 2010/06/18).
100. Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2011;(12):Cd007443 (Epub 2011/12/14).
101. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21–35 (Epub 2013/11/28).
102. Sang LX, Chang B, Zhang WL, et al. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol. 2010;16(15):1908–15 (Epub 2010/04/17).
103. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–59 (quiz 60. Epub 2011/03/17).
104. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65.e1-3 (Epub 2011/11/09).
105. Ma C, Huang V, Fedorak DK, et al. Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response. J Clin Gastroenterol. 2015;49(8):675–82 (Epub 2014/11/13).
106. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–38 (Epub 2007/05/02).
107. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95 (Epub 2010/04/16).
108. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70.e5 (quiz e31. Epub 2011/09/29).
109. Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381–92 (Epub 2014/06/22).
110. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52(7):1986–92 (Epub 2005/06/30).
111. Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31(6):931–6 (Epub 2012/02/22).
112. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1–58
113. Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22 (Epub 2015/12/08).
114. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterological Assoc. 2006;4(5):621–30 (Epub 2006/05/09).
115. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109(2):212–23 (Epub 2014/01/08).
116. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepat Off Clin Pract J Am Gastroenterol Assoc. 2009;7(8):874–81 (Epub 2009/06/30).
117. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(1):36–41.e1 (Epub 2010/10/05).
118. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76 (Epub 2005/12/13).
119. Lochs H, Dejong C, Hammarqvist F, et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr (Edinb, Scotl). 2006;25(2):260–74 (Epub 2006/05/16).
120. Jowett SL, Seal CJ, Phillips E, et al. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr (Edinb, Scotl). 2004;23(2):161–70 (Epub 2004/03/20).
121. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;(1):Cd000542 (Epub 2007/01/27).
122. Okada M, Yao T, Yamamoto T, et al. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn’s disease. Hepatogastroenterology. 1990;37(1):72–80 (Epub 1990/02/01).
123. Diagnostic criteria for and management of ulcerative colitis and Crohn’ disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014.
124. Messori A, Trallori G, D’Albasio G, et al. Defined-formula diets versus steroids in the treatment of active Crohn’s disease: a meta-analysis. Scand J Gastroenterol. 1996;31(3):267–72 (Epub 1996/03/01).
125. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333–40 (Epub 2006/10/25).
126. Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2000;32(9):769–74 (Epub 2001/02/24).
127. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;(3):Cd005984 (Epub 2007/07/20).
128. Matsui T, Ueki M, Yamada M, et al. Indications and options of nutritional treatment for Crohn’s disease. A comparison of elemental and polymeric diets. J Gastroenterol. 1995;30(Suppl 8):95–7 (Epub 1995/11/01).
129. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135(2):400–9 (Epub 2008/07/08).
130. Zhu M, Xu X, Nie F, et al. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis. 2011;26(8):999–1007 (Epub 2011/04/09).
131. Sigurbjornsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5(9):509–16 (Epub 2008/07/31).
132. Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104(12):2990–5 (Epub 2009/09/03).
133. Fukuda Y, Matsui T, Suzuki Y, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol. 2004;39(12):1158–64 (Epub 2004/12/29).
134. Fukunaga K, Yokoyama Y, Kamokozuru K, et al. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6(4):427–33 (Epub 2012/11/22).
135. Tate D, Cairnes V, Valori R, et al. First successful use of leukocyte apheresis as maintenance therapy for Crohn’s disease in the United Kingdom. J Clin Apher. 2014;29(3):181–2 (Epub 2013/11/19).
136. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030 (Epub 2012/10/09).
137. Guidelines for surgical treatment of ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014.
138. Heikens JT, de Vries J, van Laarhoven CJ. Quality of life, health-related quality of life and health status in patients having restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review. Colorectal Dis Off J Assoc Coloproctol Gt Br Irel. 2012;14(5):536–44 (Epub 2010/12/24).
139. Kuruvilla K, Osler T, Hyman NH. A comparison of the quality of life of ulcerative colitis patients after IPAA vs ileostomy. Dis Colon Rectum. 2012;55(11):1131–7 (Epub 2012/10/10).
140. da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg. 2010;97(1):65–9 (Epub 2009/12/17).
141. Thirlby RC, Land JC, Fenster LF, et al. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg (Chic, Ill: 1960). 1998;133(8):826–32 (Epub 1998/08/26).
142. Tillinger W, Mittermaier C, Lochs H, et al. Health-related quality of life in patients with Crohn’s disease: influence of surgical operation—a prospective trial. Dig Dis Sci. 1999;44(5):932–8 (Epub 1999/05/11).
143. Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257(4):679–85 (Epub 2013/01/10).
144. de Silva S, Ma C, Proulx MC, et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(11):972–80 (Epub 2011/08/03).
145. Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn’s disease: a meta-analysis. Dis Colon Rectum. 2007;50(5):576–85 (Epub 2007/03/24).
146. Lovegrove RE, Tilney HS, Heriot AG, et al. A comparison of adverse events and functional outcomes after restorative proctocolectomy for familial adenomatous polyposis and ulcerative colitis. Dis Colon Rectum. 2006;49(9):1293–306 (Epub 2006/07/11).
147. Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007;50(8):1128–38 (Epub 2007/06/26).
148. Resegotti A, Astegiano M, Farina EC, et al. Side-to-side stapled anastomosis strongly reduces anastomotic leak rates in Crohn’s disease surgery. Dis Colon Rectum. 2005;48(3):464–8 (Epub 2005/02/19).
149. Higashi D, Futami K, Egawa Y, et al. Prevention and countermeasures for suture failure in patients with Crohn’s disease. J Jpn Soc Coloproctol. 2009;62(10):818–22.
150. Watanabe K, Sasaki I, Fukushima K, et al. Long-term incidence and characteristics of intestinal failure in Crohn’s disease: a multicenter study. J Gastroenterol. 2014;49(2):231–8 (Epub 2013/04/09).
151. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601–16 (Epub 2011/03/17).
152. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–76 (Epub 2000/05/16).
153. Regueiro M, Loftus EV Jr, Steinhart AH, et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006;12(10):972–8 (Epub 2006/10/03).
154. Regueiro M, Loftus EV Jr, Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12(10):979–94 (Epub 2006/10/03).
155. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40(6):775–81 (Epub 1997/06/01).
156. Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26(1):21–9 (Epub 2007/06/09).
157. Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):Cd005573 (Epub 2007/10/19).
158. De Ley M, de Vos R, Hommes DW, et al. Fish oil for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):Cd005986 (Epub 2007/10/19).
159. Chande N, McDonald JW, Macdonald JK, et al. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(10):Cd006774 (Epub 2010/10/12).
160. McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2004;(4):Cd004722 (Epub 2004/10/21).
161. Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation—a placebo-controlled study. Aliment Pharmacol Ther. 2013;38(3):264–73 (Epub 2013/06/06).
162. Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol. 1988;10(4):406–9 (Epub 1988/08/01).
163. Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56(2):513–22 (Epub 2010/08/03).
164. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41(1):93–7 (Epub 1998/03/24).
165. Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1567–74 (Epub 2010/01/06).
166. Hiwatashi N, Suzuki Y, Mitsuyama K, et al. Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol. 2011;46(1):46–56 (Epub 2010/09/30).
167. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137(6):1934–43.e1-3 (Epub 2009/09/22).
168. Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. BMJ. 1962;2(5302):441–3 (Epub 1962/08/18).
169. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940–87 (Epub 2006/03/15).
170. Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8(7):571–81 (Epub 2014/02/05).
171. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160(10):704–11 (Epub 2014/05/21).
172. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45(Suppl):S139–44 (Epub 2011/10/14).
173. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5(1):103–10 (Epub 2006/12/05).
174. Hart AL, Ng SC. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2010;32(5):615–27 (Epub 2010/07/16).
175. Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025–31 (Epub 2003/10/01).
176. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55(9):1255–62 (Epub 2006/02/18).
177. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008;28(5):589–97 (Epub 2008/06/14).
178. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11 (Epub 2005/06/09).
179. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52(7):998–1002 (Epub 2003/06/13).
180. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25(1):19–37 (Epub 2007/01/19).
181. Huang X, Lv B, Jin HF, et al. A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis. Eur J Clin Pharmacol. 2011;67(8):759–66 (Epub 2011/06/22).
182. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7 (Epub 2011/01/07).
183. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):660–71 (Epub 2014/02/11).
184. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27(12):1157–66 (Epub 2008/04/04).
185. Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol. 1995;7(11):1025–30 (Epub 1995/11/01).
186. d’Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997;92(7):1143–7 (Epub 1997/07/01).
187. Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis. 2007;13(9):1115–20 (Epub 2007/04/25).
188. Katz S. Update in medical therapy of ulcerative colitis: a practical approach. J Clin Gastroenterol. 2002;34(4):397–407 (Epub 2002/03/22).
189. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ (Clin Res Ed). 1992;305(6844):20–2 (Epub 1992/07/04).
190. Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30(2):126–37 (Epub 2009/04/28).
191. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004;99(6):1122–8 (Epub 2004/06/08).
192. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–60 (quiz 520. Epub 2009/07/15).
193. D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106(2):199–212 (quiz 3. Epub 2010/11/04).
194. Randall J, Singh B, Warren BF, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Sur. 2010;97(3):404–9 (Epub 2010/01/27).
195. Ikeuchi H, Yamamura H, Nakano M, et al. Prognosis following surgery for ulcerative colitis in elderly patients. J Jpn Soc Coloproctol. 2007;60:136–41.
196. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7(1):1–33 (Epub 2012/10/09).
197. Michelassi F, Lee J, Rubin M, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg. 2003;238(3):433–41 (Epub 2003/09/23).
198. Kirat HT, Remzi FH, Kiran RP, et al. Comparison of outcomes after hand-sewn versus stapled ileal pouch-anal anastomosis in 3,109 patients. Surgery. 2009;146(4):723–9 (discussion 9-30. Epub 2009/10/01).
199. Ahmed Ali U, Keus F, Heikens JT, et al. Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev. 2009;(1):Cd006267 (Epub 2009/01/23).
200. Surgery JSfE. Guidelines for laparoscopic surgery for inflammatory bowel disease. Practical guidelines for endoscopic surgery. Tokyo: Kanehara & Co., LTD.; 2008. p. 54–64.
201. de Zeeuw S, Ahmed Ali U, Donders RA, et al. Update of complications and functional outcome of the ileo-pouch anal anastomosis: overview of evidence and meta-analysis of 96 observational studies. Int J Colorectal Dis. 2012;27(7):843–53 (Epub 2012/01/10).
202. Heuschen UA, Hinz U, Allemeyer EH, et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg. 2002;235(2):207–16 (Epub 2002/01/25).
203. Ikeuchi H, Uchino M, Matsuoka H, et al. Surgery for ulcerative colitis in 1,000 patients. Int J Colorectal Dis. 2010;25(8):959–65 (Epub 2010/03/11).
204. Munakata A, Hiwatashi N, Muto T, et al. Clinical effects of N-5ASA (oral controlled-release mesalazine) on Crohn’s disease: multicenter, open-label, dose-ranging study. Jpn Pharmacol Ther. 1994;22:S2531–54.
205. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology. 1993;104(5):1293–301 (Epub 1993/05/01).
206. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999;116(3):521–6 (Epub 1999/02/25).
207. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):617–29 (Epub 2011/03/17).
208. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4(1):28–62 (Epub 2010/12/03).
209. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2004;(1):Cd003574 (Epub 2004/02/20).
210. Peyrin-Biroulet L, Panes J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14(3):348–54.e17 (Epub 2015/06/15).
211. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847–69 (Epub 1979/10/01).
212. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–7 (Epub 1995/02/02).
213. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):Cd003459 (Epub 2005/01/28).
214. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35 (Epub 1997/10/09).
215. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (Lond, Engl). 2002;359(9317):1541–9 (Epub 2002/06/06).
216. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33 (quiz 591. Epub 2006/02/14).
217. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65 (Epub 2007/01/24).
218. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2008;6(6):644–53 (Epub 2008/06/14).
219. Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess (Winch, Engl). 2011;15(6):1–244 (Epub 2011/02/05).
220. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96(3):635–43 (Epub 2001/03/31).
221. Shaffer JA, Williams SE, Turnberg LA, et al. Absorption of prednisolone in patients with Crohn’s disease. Gut. 1983;24(3):182–6 (Epub 1983/03/01).
222. Futami K. Development of therapeutic guidelines for anal lesions of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2013. p. 53–4.
223. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4(1):63–101 (Epub 2010/12/03).
224. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132–42 (Epub 1995/07/15).
225. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology. 1980;79(2):357–65 (Epub 1980/08/01).
226. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405 (Epub 1999/05/06).
227. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85 (Epub 2004/02/27).
228. Judge T, Lichtenstein G. Fistulizing Crohn’s disease. Kirsner’s inflammatory bowel diseases. 6th ed. Edinburgh: Saunders; 2004. p. 700–16.
229. Keshaw H, Foong KS, Forbes A, et al. Perianal fistulae in Crohn’s disease: current and future approaches to treatment. Inflamm Bowel Dis. 2010;16(5):870–80 (Epub 2009/10/17).
230. Tozer PJ, Burling D, Gupta A, et al. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther. 2011;33(1):5–22 (Epub 2010/11/19).
231. Vavricka SR, Rogler G. Fistula treatment: the unresolved challenge. Dig Dis (Basel, Switz). 2010;28(3):556–64 (Epub 2010/10/12).
232. Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292–9 (Epub 2013/03/26).
233. Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn’s disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol. 2014;109(9):1443–9 (Epub 2014/08/06).
234. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122(2):512–30 (Epub 2002/02/08).
235. Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26(11–12):1457–64 (Epub 2007/10/02).
236. Ono Y, Hirai F, Matsui T, et al. Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with Crohn’s disease. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2012;24(6):432–8 (Epub 2012/10/20).
237. Honzawa Y, Nakase H, Matsuura M, et al. Prior use of immunomodulatory drugs improves the clinical outcome of endoscopic balloon dilation for intestinal stricture in patients with Crohn’s disease. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2013;25(5):535–43 (Epub 2013/02/01).
238. Belaiche J, Louis E. Severe lower gastrointestinal bleeding in Crohn’s disease: successful control with infliximab. Am J Gastroenterol. 2002;97(12):3210–1 (Epub 2002/12/21).
239. Aniwan S, Eakpongpaisit S, Imraporn B, et al. Infliximab stopped severe gastrointestinal bleeding in Crohn’s disease. World J Gastroenterol. 2012;18(21):2730–4 (Epub 2012/06/13).
240. Kim KJ, Han BJ, Yang SK, et al. Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2012;44(9):723–8 (Epub 2012/04/14).
241. Homan WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn disease. Report of seven cases and review of the literature. Arch Surg (Chicago, Ill: 1960). 1976;111(8):901–5 (Epub 1976/08/01).
242. Alla VM, Ojili V, Gorthi J, et al. Revisiting the past: intra-arterial vasopressin for severe gastrointestinal bleeding in Crohn’s disease. J Crohns Colitis. 2010;4(4):479–82 (Epub 2010/12/03).
243. Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn’s disease. Ann Surg. 1991;213(3):207–11 (Epub 1991/03/01).
244. Belaiche J, Louis E, D’Haens G, et al. Acute lower gastrointestinal bleeding in Crohn’s disease: characteristics of a unique series of 34 patients. Belgian IBD Research Group. Am J Gastroenterol. 1999;94(8):2177–81 (Epub 1999/08/13).
245. Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn’s disease. J Gastroenterol. 2004;39(5):441–8 (Epub 2004/06/04).
246. Potthast S, Rieber A, Von Tirpitz C, et al. Ultrasound and magnetic resonance imaging in Crohn’s disease: a comparison. Eur Radiol. 2002;12(6):1416–22 (Epub 2002/06/04).
247. Gervais DA, Hahn PF, O’Neill MJ, et al. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology. 2002;222(3):645–51 (Epub 2002/02/28).
248. Gutierrez A, Lee H, Sands BE. Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn’s disease. Am J Gastroenterol. 2006;101(10):2283–9 (Epub 2006/10/13).
249. Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23(8):1127–36 (Epub 2006/04/14).
250. van Hogezand RA, Witte AM, Veenendaal RA, et al. Proximal Crohn’s disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis. 2001;7(4):328–37 (Epub 2001/11/27).
251. Mottet C, Juillerat P, Pittet V, et al. Upper gastrointestinal Crohn’s disease. Digestion. 2007;76(2):136–40 (Epub 2008/02/02).
252. Ando Y, Matsushita M, Kawamata S, et al. Infliximab for severe gastrointestinal bleeding in Crohn’s disease. Inflamm Bowel Dis. 2009;15(3):483–4 (Epub 2008/08/01).
253. Nagamata H, Torii A, Izumi M, et al. A case of Crohn’s disease that shows the improvement of the gastric disorder by the administration of mesalazine powder. Nihon Shokakibyo Gakkai zasshi = Jpn J Gastro-enterol. 2000;97(10):1261–6 (Epub 2000/11/15).
254. Matsui T, Hatakeyama S, Ikeda K, et al. Long-term outcome of endoscopic balloon dilation in obstructive gastroduodenal Crohn’s disease. Endoscopy. 1997;29(7):640–5 (Epub 1997/11/14).
255. Tonelli F, Alemanno G, Bellucci F, et al. Symptomatic duodenal Crohn’s disease: is strictureplasty the right choice? J Crohns Colitis. 2013;7(10):791–6 (Epub 2012/11/21).
256. Mottet C, Vader JP, Felley C, et al. Appropriate management of special situations in Crohn’s disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis. 2009;3(4):257–63 (Epub 2010/12/22).
257. Magro F, Rodrigues-Pinto E, Coelho R, et al. Is it possible to change phenotype progression in Crohn’s disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol. 2014;109(7):1026–36 (Epub 2014/05/07).
258. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology. 1990;98(5 Pt 1):1123–8 (Epub 1990/05/01).
259. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54(10):1481–91 (Epub 2005/09/16).
260. Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s disease. Aliment Pharmacol Ther. 2008;27(1):11–8 (Epub 2007/10/09).
261. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;(2):Cd000067 (Epub 2000/05/05).
262. Yamamoto T, Nakahigashi M, Saniabadi AR, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13(12):1493–501 (Epub 2007/09/20).
263. Keller J, Panter H, Layer P. Management of the short bowel syndrome after extensive small bowel resection. Best Pract Res Clin Gastroenterol. 2004;18(5):977–92 (Epub 2004/10/21).
264. Erkelens GW, van Deventer SJ. Endoscopic treatment of strictures in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2004;18(1):201–7 (Epub 2004/05/05).
265. Feagins LA, Holubar SD, Kane SV, et al. Current strategies in the management of intra-abdominal abscesses in Crohn’s disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(10):842–50 (Epub 2011/06/18).
266. Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996;224(4):563–71 (discussion 71-3. Epub 1996/10/01).
267. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50(11):1968–86 (Epub 2007/09/01).
268. Simillis C, Purkayastha S, Yamamoto T, et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn’s disease. Dis Colon Rectum. 2007;50(10):1674–87 (Epub 2007/08/09).
269. McLeod RS, Wolff BG, Ross S, et al. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009;52(5):919–27 (Epub 2009/06/09).
270. Lesperance K, Martin MJ, Lehmann R, et al. National trends and outcomes for the surgical therapy of ileocolonic Crohn’s disease: a population-based analysis of laparoscopic vs. open approaches. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2009;13(7):1251–9 (Epub 2009/03/21).
271. Dasari BV, McKay D, Gardiner K. Laparoscopic versus open surgery for small bowel Crohn’s disease. Cochrane Database Syst Rev. 2011;(1):Cd006956 (Epub 2011/01/21).
272. Shinozaki M. Crohn’s disease and intestinal cancer in Japan. J Jpn Soc Coloproctol. 2008;61:353–63.
273. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25(6):665–72 (Epub 1984/06/01).
274. Williams JG, Wong WD, Rothenberger DA, et al. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78(1):10–9 (Epub 1991/01/01).
275. Fukushima T, Sugita A, Baba S, et al. Analysis of factors for postoperative recurrence of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 1996. p. 58–60.
276. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev. 2009;(4):Cd006873 (Epub 2009/10/13).
277. El Miedany Y, Youssef S, Ahmed I, et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311–7 (Epub 2006/02/04).
278. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(2):203–11 (Epub 2006/02/14).
279. Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53(2):273–83 (Epub 2005/07/16).
280. Binus AM, Qureshi AA, Li VW, et al. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(6):1244–50 (Epub 2011/08/10).
281. Ohmori T, Yamagiwa A, Nakamura I, et al. Treatment of pyoderma gangrenosum associated with Crohn’s disease. Am J Gastroenterol. 2003;98(9):2101–2 (Epub 2003/09/23).
282. Fujimoto E, Fujimoto N, Kuroda K, et al. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol. 2004;151(5):1090–2 (Epub 2004/11/16).
283. Okuma K, Mitsuishi K, Hasegawa T, et al. A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apheresis Dial Off Peer Rev J Int Soc Apheresis Jpn Soc Apheresis Jpn Soc Dial Ther. 2007;11(5):387–90 (Epub 2007/09/12).
284. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9 (Epub 2005/09/29).
285. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (Lond, Engl). 2002;359(9313):1187–93 (Epub 2002/04/17).
286. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10(6):639–45 (Epub 2012/02/01).
287. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74, 74.e1-4 (quiz e12-3. Epub 2010/02/10).
288. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53(2):256–60 (Epub 2004/01/16).
289. Omata F, Ohde S, Deshpande GA, et al. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. Scand J Gastroenterol. 2014;49(2):222–37 (Epub 2013/12/18).
290. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology. 2006;130(4):1039–46 (Epub 2006/04/19).
291. Yano Y, Matsui T, Hirai F, et al. Cancer risk in Japanese Crohn’s disease patients: investigation of the standardized incidence ratio. J Gastroenterol Hepatol. 2013;28(8):1300–5 (Epub 2013/03/16).
292. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn’s colitis. Gastroenterology. 2001;120(4):820–6 (Epub 2001/03/07).
293. Sugita A. Clinical characteristics and prognosis of small intestinal and colorectal cancers associated with ulcerative colitis and Crohn’s disease (10th report)—a proposal for the establishment of surveillance program for recto-anal cancer associated with Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2015.
294. Minakami H, Maeda T, Fujii T, et al. Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2014 edition. J Obstet Gynaecol Res. 2014;40(6):1469–99.
295. Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55(11):1575–80 (Epub 2006/06/15).
296. O’Morain C, Smethurst P, Dore CJ, et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984;25(10):1078–84 (Epub 1984/10/01).
297. Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003–2006. Aliment Pharmacol Ther. 2011;34(7):724–34 (Epub 2011/08/06).
298. Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17(3):795–801 (Epub 2010/06/22).
299. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9(2):107–24 (Epub 2015/01/21).
300. Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014;11(2):116–27 (Epub 2013/07/31).
301. Tavernier N, Fumery M, Peyrin-Biroulet L, et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(8):847–53 (Epub 2013/09/06).
302. Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohns Colitis. 2011;5(4):317–23 (Epub 2011/06/21).
303. Ujihara M, Ando T, Ishiguro K, et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. BMC Res Notes. 2013;6:210 (Epub 2013/05/28).
304. Sato A, Naganuma M, Asakura K, et al. Conception outcomes and opinions about pregnancy for men with inflammatory bowel disease. J Crohns Colitis. 2010;4(2):183–8 (Epub 2010/12/03).
305. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia: Lippincott Williams & Wilkins; 2012.
306. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22 (Epub 2012/03/22).
307. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108(9):1426–38 (Epub 2013/06/12).
308. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118–26 (Epub 2000/07/13).
309. Cheent K, Nolan J, Shariq S, et al. Case report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4(5):603–5 (Epub 2010/12/03).
310. Diseases JSfPI. Guideline of vaccination for pediatric transplant recipients and immunocompromised hosts. 2014.
311. Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–23 (Epub 2015/02/06).
312. del Val JH. Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol. 2011;17(22):2734–9 (Epub 2011/07/08).
313. Fujimoto T, Kato J, Nasu J, et al. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol Hepatol. 2007;19(3):229–35 (Epub 2007/02/16).
314. Miura S. Research on the current situation of the management of elderly patients with inflammatory bowel disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014. p. 146–51.
315. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(1):30–5 (Epub 2010/10/19).
316. Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44(1):39–43 (Epub 2013/04/05).